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SUMMARY 53 
 54 
Intron retention (IR) has emerged as an important mechanism of gene expression control.  Despite 55 
this, the factors that control IR events remain poorly understood.  We observed consistent IR in one 56 
intron of the Irf7 gene and identified Bud13 as an RNA-binding protein that acts at this intron to 57 
increase the amount of successful splicing.  Deficiency in Bud13 led to increased IR, decreased 58 
mature Irf7 transcript and protein levels, and consequently to a dampened type I interferon 59 
response.  This impairment of Irf7 production in Bud13-deficient cells compromised their ability to 60 
withstand VSV infection.  Global analysis of Bud13 knockdown and BUD13 cross-linking to RNA 61 
revealed a subset of introns that share many characteristics with the one found in Irf7 and are 62 
spliced in a Bud13-dependent manner.  Deficiency of Bud13 led to decreased mature transcript from 63 
genes containing such introns.  Thus, by acting as an antagonist to IR, Bud13 facilitates the 64 
expression of genes at which IR occurs. 65 
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INTRODUCTION 94 
 95 
Three forms of alternative processing of a pre-mRNA have been described: differential 110 
inclusion of an exon, alternative splice site selection, and intron retention (IR).  The latter, IR, has 111 
emerged as a previously underappreciated mechanism of post-transcriptional gene regulation.  112 
Unlike the two alternative splicing events, IR rarely contributes to proteomic diversity.1 However, IR 113 
events have the ability to act as negative regulators of gene expression by: (1) delaying onset of 114 
gene expression by slowing down splicing kinetics, (2) increasing potential nuclear degradation by 115 
nuclear exosomes, (3) increasing potential cytoplasmic degradation by nonsense mediated decay.2  116 
Recent genomic studies suggest IR plays an important role in the regulation of gene 117 
expression in a wide range of processes including cellular differentiation3,4 and tumorigenesis.5 118 
Further, widespread IR throughout mouse and human cell and tissue types has led to the idea that 119 
IR events act to functionally “tune” the transcriptome of a cell.6 However, with few exceptions, the 120 
factors that control IR events and thus potentially shape gene expression programs of cells, remain 121 
poorly understood.  122 
Irf7 is an interferon-inducible master regulator of the type-I interferon-dependent immune 123 
response and is crucial to the production of interferon- and .7 Aberrant Irf7 production is linked to 124 
a wide range of pathologies, from life-threatening influenza8 to autoimmunity9, because precise 125 
regulation of Irf7 ensures a proper immune response. Notably, intron 4 of Irf7 is short, GC-rich, and 126 
has a poor splice donor sequence, characteristics shared by many poorly spliced introns.  We and 127 
others have previously shown that intron 4 of Irf7 splices inefficiently10, affecting gene expression 128 
and opening a new line of inquiry as to the mechanism of IR regulation in Irf7.  129 
Using RNA antisense purification-mass spectrometry (RAP-MS)11, we identified the protein 130 
Bud13 as one that regulates IR in Irf7.  Bud13 was found to aid splicing efficiency and expression of 131 
the Irf7 mature transcript and protein, thus promoting the downstream type-I interferon-dependent 132 
immune response.  We show that Irf7 is able to trigger a robust interferon response in the presence 133 
but not in the absence of Bud13.  Further, Bud13 was found to increase the splicing efficiency of a 134 
multitude of other junctions with similar characteristics to the one found in Irf7.  By aiding in splicing 135 
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efficiency, Bud13 limits intron retention and increases gene expression levels of transcripts 136 
containing Bud13 dependent junctions.  137 
 138 
RESULTS 139 
 140 
Irf7 contains an intron that splices poorly following stimulation.  141 
 142 
To study the role of mRNA splicing during an innate immune response, we sequenced the 143 
RNA from mouse bone marrow-derived macrophages (BMDMs) stimulated with either TNFα, IFNα, 144 
or Poly(I:C).  From this sequencing, we identified an increased number of intronic reads in the fourth 145 
intron of the most abundant transcript of Irf7 (Fig. 1A). A variety of features of this intron make it a 146 
likely candidate for retention.6  It is extremely small at 69 nucleotides and has a high G/C content in 147 
both the flanking exons and within the intron itself (Fig. 1B-E).  Furthermore, the intron contains a 148 
‘weak’ 5’ splice site, one that deviates significantly from a consensus splice site sequence.  This is 149 
quantified using a maximum entropy model to calculate the splice site quality score (Fig. 1F).12  This 150 
retention is independent of time or stimulant (Fig. 1G, H). 151 
To quantify the extent of retention across RNA-seq data-sets, we use a metric we designate 152 
the “splicing ratio” (SR) (Fig. 1I; see methods), which is a length normalized ratio of intronic reads to 153 
total reads at each junction.  Low SR values indicate a junction is primarily spliced whereas high SR 154 
values indicate a junction is primarily unspliced.  Using this metric, we quantified the extent of 155 
retention for all junctions in the most abundant Irf7 transcript.  We observed that for all types of 156 
stimulation, the retention of the fourth intron of the transcript is much greater than that seen for any 157 
of the other introns (Fig. 1J and S1A, B). This intron remains poorly spliced despite the fact that 158 
there is clear excision of neighboring introns.  It is worth noting that quantitation of the IFNα 159 
stimulation shows increased intronic signal throughout the Irf7 transcript.  This increased intronic 160 
signal is due to faster and stronger induction of Irf7 via stimulation with IFNα and as such, an 161 
increase in the amount of pre-mRNA at a given stimulation time-point.  Despite this increase in 162 
intronic signal throughout the transcript, we observed a corresponding increase in the level of 163 
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retention for the poorly spliced fourth intron (Fig. 1J, S1B).  Thus, we conclude this intron of Irf7 164 
splices poorly following many forms of stimulation. 165 
 166 
RAP-MS identifies Bud13 as an RNA binding protein that interacts with IRF7 mRNA. 167 
 168 
To understand how cells handle a retained intron, we sought to identify trans-acting proteins 169 
that might affect the process using RNA Antisense Purification followed by Mass Spectrometry (RAP-170 
MS) (Fig. 2A)11.  RAP-MS employs antisense biotin-containing ssDNAs complementary to Irf7 exons 171 
to purify the proteins associated with the total pool of Irf7 transcripts, containing both nascent pre-172 
mRNAs and mature mRNA. Using this proteomic approach, we identified the RNA-binding protein 173 
Bud13 to be highly enriched (~6-fold) on Irf7 transcripts as compared to β-actin transcripts, which were 174 
used as a control (Fig. 2B).  Bud13 has been characterized in yeast as a member of the Retention 175 
and Splicing complex (RES),13 forming a trimeric complex with Pml1p and Snu17p, and aids in the 176 
splicing and nuclear retention of a subset of transcripts. It is not well characterized in mammalian 177 
systems.  We captured a variety of other known RNA-binding proteins (Pum2, Prpf40a, Son); however, 178 
no other protein was enriched greater than two fold on Irf7 transcripts.  We observed specificity in the 179 
RNA antisense purification for the intended transcripts (Fig. 2C).    180 
Following RAP-MS, we confirmed Bud13 enrichment on Irf7 transcripts by performing RNA 181 
Immunoprecipitation (RIP) followed by qPCR.  Using formaldehyde cross-linked, BMDMs stimulated 182 
with TNFα for 30 minutes or Poly(I:C) for 12 hours, we observed >7-fold enrichment of Irf7 transcripts 183 
associated with Bud13 immunoprecipitates as compared to Rabbit IgG control immunoprecipitates 184 
(Fig. 2D, E).  Of note, despite using two different stimuli, we find similar levels of enrichment. In 185 
contrast, no differential enrichment of Rpl32 was observed.  Thus, isolating the proteins associated 186 
with Irf7 mRNA transcripts led to the identification of Bud13, and immunoprecipitation of Bud13 protein 187 
confirmed enrichment of Irf7 mRNA.   188 
 189 
 190 
 191 
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Bud13 knockdown leads to increased retention in the weak Irf7 intron. 192 
 193 
To determine whether the enrichment of Bud13 had an effect on Irf7 mRNA processing, we 194 
used an shRNA approach to knockdown Bud13 protein levels in BMDMs (Fig. S2A, B).  To quantify 195 
differences in splicing between the shBud13 sample and the scrambled control sample, we calculated 196 
the difference in the previously mentioned splicing ratio (SR) metric between shBud13 and control for 197 
each junction at each time point.  This resulting value was designated the ΔSR. A positive ΔSR 198 
indicates a junction is more unspliced in the shBud13 sample while a negative ΔSR indicates a junction 199 
is more unspliced in the control sample.  200 
 RNA-seq was performed on RNA from unstimulated BMDMs, as well as macrophages 201 
stimulated with TNFα for 0, 30, 60, and 120 minutes.  Bud13 knockdown led to a further increased 202 
retention of the fourth intron in Irf7 (Fig. 3A – highlighted intron, S2C).  Further, the sequencing 203 
coverage plots showed little variation in splicing for the other seven introns in the transcript.  This was 204 
confirmed when splicing was quantified using the ΔSR metric (Fig. 3B).  This splicing difference was 205 
confirmed via RT-PCR (Fig. 3C).  At all stimulation time-points, the ΔSR value for the fourth intron was 206 
significantly greater than 0, indicating an increase in retention when Bud13 levels were reduced.  There 207 
is a significant difference in the ΔSR of intron 4 as compared to every other junction in the Irf7 transcript 208 
(p<0.001, Student’s t-test).  All other pairwise comparisons are insignificant.  It appears that Bud13 209 
plays a specific role of aiding in the excision of the poorly spliced junction but is not required for total 210 
splicing of other introns in the transcript, at least as indicated by the partial knockdown with an shRNA.  211 
We next looked at how this retention affected the induction kinetics of Irf7.  We observed decreased 212 
induction of Irf7 mRNA in response to TNFα stimulation in shBud13 BMDMs as compared to control 213 
BMDMs (Fig. 3D), consistent with the idea that intron retention leads to transcript degradation.14 Other 214 
TNFα induced transcripts that lacked a Bud13 dependent splicing defect showed similar induction 215 
between the time-courses (Fig. S2 D-F). 216 
 217 
 218 
 219 
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Bud13 knockdown alters the type I interferon response. 220 
 221 
Because Irf7 is known as a ‘master regulator’ for robust type I interferon production7, we next 222 
investigated the effect of Bud13 knockdown on a type I interferon response. To do so, we stimulated 223 
BMDMs with the TLR3 agonist Poly(I:C) for up to 24 hours.  Activation of TLR3 leads to the production 224 
of type I interferons followed by the downstream induction and activation of Irf7, which serves to 225 
amplify the type I interferon response via positive feedback8. We again observed differential splicing 226 
between the shBud13 samples and the control samples in intron 4 of Irf7 (Fig. 4A, S3A).  As before, 227 
there is a significant difference in the ΔSR of intron 4 as compared to every other junction in the Irf7 228 
transcript (Fig. 4B. p<0.001, Student’s t-test), whereas all other pairwise comparisons are insignificant.  229 
As is the case with TNFα, knocking down Bud13 altered Irf7 induction kinetics.  Less Irf7 mRNA is 230 
induced at 240, 720, and 1440mins of poly(I:C) stimulation (Fig. 4C).  This reduction in Irf7 mRNA 231 
leads to a decrease in the amount of Irf7 protein produced (Fig. 4D).   232 
Next we looked at how this reduction in Irf7 would alter the production of RNA from interferon 233 
signature genes (ISGs).  Expression of 119 ISGs (selected based on upregulation in response to IFNα 234 
15; see methods) was examined. In unstimulated BMDMs, used as a baseline, the median log2 235 
expression fold change (FPKM shBud13/ FPKM control) is 0.1655 (Fig. 4D).  In contrast, at 720 mins 236 
of stimulation, the median log2 expression fold change shifts to -0.1007 (Fig. 4E), indicating a 237 
significant decrease in ISG expression in the shBud13 sample compared to the control sample at this 238 
time-point compared to the baseline (Wilcoxon rank-sum, P< .001). This significant decrease in ISG 239 
expression remained true when comparing any of the ‘early’ time points (0, 15, 60 mins) to any of the 240 
‘late’ timepoints (240, 720, 1440 mins) (Fig. 4G, Wilcoxon rank-sum, P<0.001).  qPCR was used to 241 
monitor expression of both IFNα and IFN following 720 and 1440 mins of Poly(I:C) stimulation.  We 242 
observed significant reduction in both when comparing the shBud13 samples as to the control samples 243 
(Fig. 4H, I).  To ensure differential expression of ISGs was not due to splicing defects from Bud13 244 
knockdown, we quantified the ΔSR for every ISG junction at 720 mins.  The fourth intron of Irf7 has 245 
the greatest ΔSR at 0.227. Only four other junctions of the 375 that were examined have ΔSRs greater 246 
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than 0.1, and the majority of junctions have ΔSRs close to 0 (Fig. S3C; mean = 0.002, median = 0).  247 
Similar results were obtained when BMDMs were stimulated with the TLR9 agonist CpG (Figure S4). 248 
Taken together, we conclude that Bud13 deficiency results in a highly compromised type I interferon 249 
response. 250 
We next examined whether Irf7 pre-mRNA with a retained fourth intron was able to exit the 251 
nucleus and enter the cytoplasm.  BMDMs were stimulated with poly(I:C) and fractionated into a 252 
nuclear fraction (containing the nucleoplasm and chromatin) and a cytoplasmic fraction.  RNA-seq 253 
was performed on both fractions.  In the cytoplasm, we found Irf7 mRNA to be completely spliced (Fig. 254 
4J, K).  Thus, unspliced Irf7 is either being degraded in the nucleus, or it makes it to the cytoplasm 255 
and is degraded extremely quickly, such that virtually no signal can be detected via RNA-seq.  256 
Furthermore, in support of our whole cell sequencing data and Irf7 immunoblots, we observed less 257 
Irf7 mRNA in the cytoplasm in shBud13 samples as compared to control samples (Fig. 4L).  In the 258 
nucleus, although we notice a large number of unspliced reads at all junctions in both samples, the 259 
fourth intron of Irf7 again showed a specific dependency on Bud13 (Fig. 4K, S5B).  Finally, the fourth 260 
intron had a greater RPKM in the nucleus in shBud13 compared to control BMDMs across the 261 
stimulation time-course (Fig. 4K) and had a significantly greater nuclear ΔSR than any other junctions 262 
in the transcript (Fig S5B). 263 
Global analysis of the role of Bud13 in BMDMs. 264 
We next investigated global splicing differences caused by Bud13 knockdown.  Using the 265 
TNFα stimulated data-set, ΔSR was calculated for every junction in every expressed gene.  We 266 
found that a number of other transcripts had a Bud13 dependent junction (Fig. 5A).  Of note, the 267 
fourth intron of Irf7 is among the most Bud13 dependent junctions in both the TNFα and Poly(I:C) 268 
data-sets (Fig. 5A., Fig. S6H, see methods for analysis details).  Similar to the case with Irf7, almost 269 
all transcripts contain only a single Bud13 dependent junction, even when low thresholds are used to 270 
quantify dependency (Fig. 5B).  To determine whether splicing differences caused by Bud13 271 
knockdown led to altered gene expression, we compared the effect of the Bud13 knockdown on 272 
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genes that contained a Bud13 dependent junction to those that did not. (see methods).  The median 273 
log2 expression fold change (FPKM shBud13/ FPKM control) for genes containing a Bud13 274 
dependent junction was -0.5084.  In contrast, the median log2 expression fold change (FPKM 275 
shBud13/ FPKM control) for genes without any junctions affected by Bud13 knockdown was -0.2170.  276 
Thus, we conclude there is an inverse relationship between IR due to Bud13 knockdown and gene 277 
expression (Wilcoxon rank-sum, P< .01) (Fig. 5C).   278 
 Next, it was of interest to us to identify sequence elements that led Bud13 to have its specific 279 
splicing effect. The most evident element to explore was the effect of splice site strength on Bud13-280 
dependent splicing.  Previous work has shown that the yeast orthologue of Bud13 plays a role in 281 
efficient splicing for a junction with a weak 5’ splice site13.  Further, the junction affected in Irf7 has a 282 
non-consensus 5’ splice site.  To investigate this issue, we first quantified every 5’ and 3’ splice site 283 
using a maximum entropy model.12 Then, we took progressively weaker splice site thresholds, and 284 
compared the mean ΔSR for every junction below that threshold to the mean ΔSR of every junction in 285 
the data-set (Fig. 5D).  We saw that as the splice site threshold for the 5’ splice site became 286 
progressively weaker, the mean ΔSR for junctions weaker than that threshold increased and thus 287 
there was a greater Bud13 splicing effect.  This result was not seen when the same analysis was 288 
applied to the 3’ splice site.  In support of a 5’ splice site dependency for a Bud13 effect, we noticed 289 
differences in the 5’ splice site motif of Bud13 dependent junctions as compared to to all expressed 290 
junctions (Fig. 5E).  291 
We then analyzed the Bud13 splicing effect with respect to other features known to correlate 292 
with IR.6  Across all time-points for both TNFα (Fig. 5F-H) and Poly(I:C) (Fig. S7 A-C), Bud13 293 
dependent introns were dramatically smaller and had increased G/C content in both the intron and in 294 
the flanking exons.  We also noticed that the distance from the branch point to the 3’ splice site was 295 
smaller in the Bud13 dependent introns than in the total data-set (Fig. 5I, Fig. S7D).  This could be a 296 
byproduct of the smaller intron length; however, it is of interest because Bud13 has been shown in 297 
yeast to bind just downstream of the branch point.16  A significant difference was not seen in branch 298 
point strength and Bud13 splicing effect (Fig. S7 E, F).  As IR is only one form of alternative splicing, 299 
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we also looked at whether other forms of alternative splicing were affected by Bud13 knockdown.  We 300 
found that the most statistically significant number of alternative splicing events were IR events (Fig. 301 
S7G, see methods).  There were three-times as many IR events as the next most alternative splicing 302 
event.  IR at intron 4 in Irf7 was the only alternative splicing event that occurred in transcripts related 303 
to the type I interferon response. 304 
eCLIP shows enrichment on Bud13 dependent junctions near the 3’ splice site. 305 
 Next we used enhanced crosslinking and immunopreciptation (eCLIP)-seq data from the 306 
ENCODE Project Consortium17 to investigate Bud13 binding specificity across the genome.  We 307 
found that in K562 and Hep G2 cells, the majority of Bud13 eCLIP-sequencing reads were located 308 
downstream of the branchpoint near the 3’ splice site (Fig. 6A, B), consistent with what is seen in 309 
yeast.16  Plots are shown as a measure of binding over input.  There is some read density near the 310 
5’ splice site, which we hypothesize is due to Bud13’s association with the spliceosome.  Although it 311 
may not bind near the 5’ splice site, factors in the spliceosome that interact with Bud13 may 312 
immunoprecipitate with Bud13, leading to 5’ signal.  Data for Sf3b4 and Prpf8, known RBPs that 313 
interact with the 3’ and 5’ splice site respectively, is also shown for comparison (Fig. 6A, B).  We 314 
hypothesized that Bud13 binding would correlate with Bud13 activity.  To test this hypothesis, we 315 
used knockdown data from the ENCODE Project Consortium to determine Bud13 dependent 316 
junctions in K562 and Hep G2 cells.  In K562 cells, we noticed that there was a significant increase 317 
in Bud13 binding over input at Bud13 dependent junctions (Fig. 6A).  In Hep G2 cells, this increase 318 
was less pronounced (Fig. 6B), however, we note that we found Bud13 knockdown had a much 319 
greater impact in K562 cells as compared to Hep G2 cells (Fig. S8A).  In order to survey a large 320 
enough selection of junctions in Hep G2’s, we had to significantly lower our threshold for what was 321 
deemed a Bud13 dependent junction (see methods), which in turn might explain the dampened 322 
Bud13 binding/activity relationship in Hep G2.  We conclude that Bud13 either preferentially 323 
associates with these Bud13 dependent junctions or associates with them for a longer period of 324 
time,.   325 
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We next performed peak calling to determine the location of significant peaks.  We find the 326 
majority of peaks are in intronic regions or intron-exon junctions and that most of the peaks that lie in 327 
intron-exon junction are located at the 3’ junction (Fig. 6C, D).  As might be expected from 328 
knockdown data, when comparing introns that have an overlapping eCLIP peak to all introns from 329 
expressed transcripts, we see both a length and G/C% bias (Fig. 6E, F).  Bud13 peaks tend to fall in 330 
smaller introns that are GC rich, a finding consistent with the ΔSR data.  Lastly, a list of the GO 331 
biological processes most enriched from the list of peaks in K562 and Hep G2 cells is shown (Fig. 332 
6G).   333 
 334 
Bud13 knockdown alters the BMDM response to VSV. 335 
Vesicular stomatitis virus (VSV) is a (-)ssRNA virus known to induce type I IFN through 336 
TLR718.  To test whether impairment of Irf7 due to Bud13 knockdown was present in VSV stimulated 337 
BMDMs, we infected both shBud13 and control BMDMs at an MOI of 5 and 10.  At all time-points 338 
throughout infection in both MOIs, there was dampened Irf7 induction (Fig. 7A, B) as quantified by 339 
Taqman qPCR.  Next, in order to determine the consequences of impaired Irf7 induction, we 340 
determined the yield of virus from BMDMs following a period of infection with a given input MOI. 341 
shBud13 BMDMs produce significantly more VSV as compared to control BMDMs (Fig. 7C).  This 342 
difference in viral production is presumably due to decreased production of Irf7 and the 343 
corresponding dampened type I interferon response.  To test if a mechanism other than Irf7 intron 344 
retention may contribute to the impaired response to viral infection, we rescued Irf7 levels by 345 
expressing Irf7 cDNA either in the context of the Bud13 knockdown or the control.  We found 346 
overexpression of Irf7 cDNA effectively rescues the ability for a cell to clear virus (Fig. 7C).  As such, 347 
we conclude that the viral susceptibility associated with Bud13 knockdown is due to the increased 348 
intron retention in the fourth intron of Irf7 and the corresponding dampened type I interferon 349 
response. 350 
 351 
 352 
 353 
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DISCUSSION 354 
 355 
In this study, we sought proteins that might relate to the poor splicing of an intron in Irf7 356 
transcripts.   Using RAP-MS, we identified Bud13 as a protein that has the ability to increase splicing 357 
of the Irf7 intron.  In the absence of Bud13, in response to inflammatory stimulus, macrophages 358 
produced Irf7 with increased intron retention (IR) and notably less mature Irf7 transcript and protein 359 
(Fig. 3C, 4C, 4D, S4C).  Irf7 is the interferon-inducible master regulator of the type-I interferon-360 
dependent immune response.7  Correspondingly, depletion of Bud13 led to a general reduction in 361 
ISG and cytokine production, implying a compromised type I interferon response (Fig. 4E-J, S4D-G).  362 
This splicing and corresponding expression defect upon Bud13 depletion was observed under 363 
various stimulation regimens and times. We found that macrophages deficient for Bud13 were 364 
strikingly more susceptible to infection by VSV, presumably owing to the reduction in Irf7 transcript 365 
levels (Fig. 7). 366 
We observed the Bud13 splicing dependence in other introns of other genes.  A number of 367 
short, GC-rich introns with non-consensus splice donor sites were excised inefficiently when Bud13 368 
levels were depleted (Fig. 5).  As was the case with Irf7, this increased IR reduced mature transcript 369 
levels (Fig. 5A).  Transcripts containing retained introns have been shown in the literature to be 370 
degraded by two mechanisms: (1) nuclear degradation via the RNA exosome, (2) cytoplasmic 371 
degradation upon detection of a pre-termination codon (PTC) via the NMD decay machinery.  372 
Although the majority of these introns contain a PTC, it remains to be determined whether 373 
degradation is occurring in the nucleus or cytoplasm.14,19 374 
Bud13 was originally identified as a part of a “Retention and Splicing” (RES) complex13 in 375 
yeast. However, yeast Bud13 (ScBud13) and mammalian Bud13 are significantly different lengths 376 
(266 vs. 637 amino acids) 20, with only the mammalian protein containing a large, disordered 377 
arginine-rich N-terminal domain.  ScBud13 counteracts IR in introns within the mediator complex, 378 
mating genes, and tRNA modifying genes21–23, which in turn impair yeast budding.  In connection 379 
with the RES complex, ScBud13 is thought to safeguard formation of the ‘Bact complex’ of the 380 
spliceosome.24 In the Bact stage, the 5’ splice donor and branch point are recognized by the 381 
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spliceosome. However, progression to catalysis of the first step of the splicing reaction requires 382 
remodeling of several spliceosome components.25 Lack of the RES complex has been shown to lead 383 
to premature binding of Prp2, a quality control factor that is responsible for spliceosome remodeling 384 
as well as the disassembly of suboptimal substrates.  It has been hypothesized that ScBud13 and 385 
the RES complex temporally regulate Prp2 binding.24 In the mammalian context, short, GC-rich 386 
introns with weak donor sites may be particularly susceptible to Prp2-mediated disassembly, which 387 
may explain the specificity of IR events upon Bud13 depletion. 388 
In yeast, differential studies using mass spectrometry26 and cross-linking have established 389 
that some ScBud13 is detectable in preparations of stalled B, Bact, and B* complexes. One cryo-EM 390 
structure of the yeast spliceosome found density corresponding to ScBud13 in a stalled Bact pre-391 
catalytic complex, although a structure of the stalled B complex found only weak density for 392 
ScBud13.21,27 In mammals, structural evidence of Bud13 is limited. Given the partial sequence 393 
homology between all members of the yeast RES complex and their mammalian counterparts, it is 394 
not surprising that Bud13 (and other RES complex members) are often undetectable in preparations 395 
of stalled spliceosomes using cross-linking and mass-spectrometry. Furthermore, Bud13 was not 396 
detected in a recent human cryo-EM structure of a stalled B complex.28 Taken together, it is not yet 397 
possible to determine if the sub-stoichiometric nature of Bud13 in mammalian spliceosome 398 
complexes is because it is constitutively associated but highly transient or because it serves as a 399 
non-essential accessory to spliceosome function. Cryo-EM studies, as well as single molecule 400 
studies, would seem to suggest compositional heterogeneity of the spliceosome, and that the 401 
Bud13-endowed spliceosome may catalyze the splicing reaction in a fundamentally different way 402 
than is used in its absence.24,29,30 403 
Recently, the RES complex in zebrafish was shown to regulate levels of IR in short, GC-rich 404 
introns in knockout studies.31 Indeed, both in Zebrafish31 and C. Elegans,32  deficiency of RES 405 
components has been reported to lead to embryonic lethality. Our results show that mammalian 406 
Bud13 shares this splicing fidelity function, and deficiency may prevent proper development. Despite 407 
this, knockdown and knock-out cell lines have displayed no overt growth defects, suggesting a 408 
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developmental but not immune-cell intrinsic dependence on Bud13 for survival.  Of note, we did 409 
sequence knockdowns of the other RES components, Rbmx2 and Snip1 (Fig. S11).  We see a very 410 
mild effect on the fourth intron of Irf7, and although the fourth intron is the most affected in both 411 
cases as measured by ΔSR, it lacks statistical significance when compared to other introns in the 412 
transcript.  Further, we find very mild global IR when compared to the IR induced by Bud13 413 
knockdown.  We do not believe our data disputes what is shown in other organisms, but instead feel 414 
that either more efficient knockdowns or a total knockout would be needed to replicate the strong 415 
effect seen with Bud13 depletion. 416 
With respect to Irf7, the fact that a crucial immunological gene has such an intron, with its 417 
variety of seemingly negative characteristics that make it difficult for the spliceosome to excise, begs 418 
the question as to why it exists.  At the heart of an inflammatory response is a tightly regulated gene 419 
expression program.  Regulation of this gene expression program is crucial as small changes can 420 
shift the balance away from protective immunity towards either nonexistent or destructive 421 
immunity.33  Here we’ve shown that alterations to the splicing efficiency of the fourth intron have the 422 
ability to significantly alter the functional output of Irf7.  Thus, by existing in the Irf7 transcript and 423 
commonly being retained, it stands to reason the weak fourth intron acts to dampen Irf7 output, 424 
perhaps as a means to mitigate what otherwise would be an unchecked or inappropriately scaled 425 
response.  Whether a cell actively controls this splicing event and thus, the intron serves as a 426 
regulatory control point, remains unknown.  Further, it remains unknown whether Bud13 plays a role 427 
in this regulation or whether it simply represents a mechanism that evolved to counter intron 428 
retention in a subset of introns that require splicing but happen to be inherently weak. 429 
In summary, we found that Bud13 modulates gene expression through its ability to alter IR, 430 
often in notably small, GC-rich introns with weak splice sites.  Deficiency of Bud13 results in IR and 431 
concomitant decreased gene expression in transcripts such as Irf7, dampening the type I interferon 432 
response and increasing viral susceptibility.   Therefore Bud13, in mediating Irf7 gene expression, 433 
presents a potential therapeutic target for the treatment of infections or autoimmune conditions.  434 
Future studies should seek to understand why Bud13 is vital for the efficient splicing of only a subset 435 
All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/443820doi: bioRxiv preprint first posted online Oct. 15, 2018; 
   
   
15
of junctions and whether or not this junction specificity plays an active role in regulating gene 436 
expression. If modulated, this strategy by which components associated with the spliceosome 437 
rescue transcripts from intron retention and degradation may represent a previously 438 
underappreciated layer of regulation in many gene expression programs. 439 
 440 
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FIGURE LEGENDS 589 
Figure 1: Irf7 contains a weak intron that is following many forms of stimulation.  (A) Histogram of 590 
mapped reads corresponding to the TNFα-induced expression of Irf7.  The poorly spliced fourth intron is 591 
highlighted.  For all read density plots, reads are histogrammed in log10 scale and normalized to the 592 
maximum value across the stimulation.  (B) Comparison of Irf7 splice donor and acceptor sites in mice, 593 
rats, and humans.  (C-F) Histogram representing the intron length (C), intron GC content (D), flanking 594 
exon GC content (E), or 5’ splice site strength of introns of expressed in BMDMs.  Red represents 595 
location of Irf7 intron 4 (C, D, F) or upstream exon (E). Black line represents downstream exon (E). (G, H) 596 
Histogram of mapped reads corresponding to the IFNα (G) and poly(I:C) (H) induced expression of Irf7 597 
focused on the slow splicing fourth intron. (I) Outline of Splicing Ratio (SR) metric. (J) Splicing ratio for all 598 
introns in Irf7 plotted against time stimulated with TNFα.   599 
 600 
Figure 2: RAP-MS and RIP identifies Bud13 as an RNA binding protein that interacts with IRF7 601 
mRNA.  (A) Outline of the RAP-MS procedure used to identify RNA-binding proteins on transcritps of 602 
interest. (B)  TMT ratio (Irf7/Actb) for proteins identified as enriched on either Irf7 (TMT ratio >1) or Actb 603 
(TMT ratio <1) transcripts.  (C) RT-qPCR analysis of transcripts captured via RAP for Irf7 (blue) and Actb 604 
(gold) probes.  (D) RIP followed by RT-qPCR for Irf7 and Rpl32 in TNFα stimulated BMDMs.  Shown is 605 
the relative enrichment of transcripts captured in Bud13 RIP as compared to Rabbit IgG RIP. (E) Same as 606 
(d) except stimulation with poly(I:C).  Data are representative of two independent experiments ((C-E), 607 
mean + SEM). *P < 0.05, **P < 0.01 and ***P < 0.001 (t-test).  608 
 609 
Figure 3: Bud13 knockdown leads to increased retention in the poorly splicing intron of Irf7.  (A) 610 
Histogram of mapped reads corresponding to the TNFα-induced expression of Irf7.  The poorly spliced 611 
fourth intron is highlighted.  shBud13 samples are shown in green.  Control samples are shown in grey. 612 
(B) ΔSRs calculated for each junction in the Irf7 transcript.  The ΔSR of intron 4 as compared to all other 613 
junctions is significant (Student’s t-test, p<0.001).  No other pairwise comparison is significant.  (C) 614 
Splicing gel from RNA extracted from BMDMS stimulated for 30 mins. TNFα (top).  Quantification of 615 
splicing gel (bottom).  (D) Irf7 FPKM fold change with respect to time stimulated.  shBud13 is shown in 616 
green, control is shown in grey. Data is representative of two independent experiments (C) and is 617 
represented as mean + SEM.  * denotes p < 0.05, ** denotes p < 0.01, and *** denotes p < 0.001 using a 618 
Student’s t test. 619 
Figure 4: Bud13 knockdown alters the type I interferon response. (A) Histogram of mapped reads 620 
corresponding to the TNFα-induced expression of Irf7.  The poorly spliced fourth intron is highlighted.  621 
shBud13 samples are shown in blue. Control samples are shown in grey. (B) ΔSRs calculated for each 622 
junction in the Irf7 transcript.  The ΔSR of intron 4 as compared to all other junctions is significant 623 
(Student’s t-test, p<0.001).  No other pairwise comparison is significant.  (C) Irf7 FPKM fold change with 624 
respect to time stimulated.  shBud13 is shown in blue, control is shown in grey.  (D) Immunoblot analysis 625 
of Irf7 protein following 720 mins. poly(I:C) stimulation (left).  Quantification relative to ActB (right). (E) 626 
Log2 expression fold change (shBud13/control) for 119 ISGs in unstimulated BMDMs (median = 0.1655). 627 
(F) As in (E) for stimulated BMDMs (720 mins poly(I:C) (median = -0.1007). Wilcoxon rank-sum between 628 
(E) and (F), P< .001.  (G) Median log2 expression fold change (shBud13/control) for ISGs in unstimulated 629 
BMDMs, and BMDMs stimulated with Poly(I:C) 15, 60, 240, 720, and 1440 mins.  Bars represent 95% CI.  630 
(Wilcoxon rank-sum, P< .001, for any of the ‘early’ time-points (0, 15, 60 mins) compared to any of the 631 
‘late’ time-points (240, 720, 1440 mins). (H) RT-qPCR analysis of IFNα mRNA levels in unstimulated 632 
BMDMs and BMDMs stimulated with poly(I:C) for 720 mins and 1440 mins. (I) Same as (H) for IFNβ. (J) 633 
Nuclear fraction (top) and cytoplasmic fraction (bottom) histograms of mapped reads corresponding to the 634 
poly(I:C)-induced expression of Irf7 (720 mins). The poorly spliced fourth intron is highlighted.  shBud13 635 
samples are shown in blue.  Control samples are shown in grey. Nuclear ΔSR = 0.35. (K) Nuclear and 636 
cytoplasmic RPKM for Irf7 intron 4 from fractionated BMDMs stimulated with poly(I:C).  (L) Cytoplasmic 637 
Irf7 FPKM for control (grey) and shBud13 BMDMs stimulated with poly(I:C).  Data is representative of four 638 
independent experiments (H, I) and is represented as mean + SEM.  * denotes p < 0.05, ** denotes p < 639 
0.01, and *** denotes p < 0.001 using a Student’s t test.  Results are presented relative to those of Rpl32 640 
(H,I). 641 
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Figure 5: Global analysis of the role of Bud13. (A) Ranked bar chart showing genes with a junction most 642 
affected by Bud13 knock-down in all samples during TNFα stimulation.  See S7 for histograms relating to 643 
most affected junctions. (B) Grouped bar chart depicting the number of genes that have a single Bud13 644 
affected junction vs. multiple Bud13 affected junctions using three different ΔSR thresholds.  (C) 645 
Transcripts were classified as ‘Bud13 dependent’ if they had a junction with a ΔSR. >0.15.  The log2 646 
expression fold change (FPKM shBud13/ FPKM control) for each gene represented by the transcripts in 647 
the ‘Bud13 dependent’ category as well as all other genes is shown.  Median ‘increased IR’ = -0.5084.  648 
Median ‘decreased IR’ = -0.2170.  (Wilcoxon rank-sum, P< .01).  (D)  Mean ΔSR. for junctions below the 649 
indicated threshold (x-axis) vs. mean ΔSR. for all junctions.  Threshold applied for the 5’ splice site (blue) 650 
and the 3’ splice site (green). (E) 5’SS motif for all expressed junctions as compared to junctions that show 651 
retention upon Bud13 knockdown (ΔSR. > 0.15). (F) Size of intron for introns retained upon Bud13 652 
knockdown (ΔSR. > 0.15) (blue), in introns located in the same transcript as those affected by Bud13 653 
(green), and in introns from all expressed transcripts (orange). (G) Same as (F) for GC content.  (H) 654 
Flanking exon GC content for exons that flank introns retained upon Bud13 knockdown (ΔSR. > 0.15) 655 
(dark green) as compared to exons that flank introns from all expressed transcripts (light green).  (I) 656 
Distance from the branch point to the 3’ splice site for introns retained upon Bud13 knockdown (ΔSR. > 657 
0.15) (dark blue) as compared to introns from all expressed transcripts (light blue).  (F-I) data from BMDM 658 
TNFα stimulation. Box plots show median (center line), interquartile range (box) and tenth and ninetieth 659 
percentiles.  *P < 0.05, **P < 0.01 and ***P < 0.001 (Mann-Whitney U-test).  660 
Figure 6: Bud13 interacts primarily near the 3’ splice site of small, GC rich introns. (A) eCLIP-seq 661 
read density plots in K562 cells.  Bud13 density plot over all expressed junctions shown in blue (top), 662 
Bud13 density plot over Bud13 dependent junctions shown in red (top). Sf3b4 density plot over all 663 
expressed junctions shown in maroon (middle), and Prpf8 density plot over all expressed junctions is 664 
shown in green (bottom).  (B) Same as in (A) but for Hep G2 cells.  (C) Bud13 eCLIP-seq peak 665 
distribution.  Peaks fell within either intronic regions, intron-exon junctions, or exonic regions.  Peaks that 666 
fell within intron-exon junction were further classified as 5’ junction peaks or 3’ junction peaks (bottom).  667 
(D) Same as (C) but for Hep G2.  (E)  Size of all introns in expressed transcripts for the given cell line 668 
(dark blue) vs size of introns with overlapping eCLIP peak (maroon).  Shown in K562 (left) and Hep G2 669 
(right) cells.  Box plots show median (center line), interquartile range (box) and tenth and ninetieth 670 
percentiles (whiskers).  *P < 0.05, **P < 0.01 and ***P < 0.001 (Mann-Whitney U-test). (F) Same as (E) 671 
for GC content.  (G) GO terms (biological process) enriched among Bud13 eCLIP peaks in K562(dark 672 
blue) and Hep G2 (maroon) cells. 673 
Figure 7: Bud13 knockdown alters the BMDM response to VSV. (A) RT-qPCR analysis of Irf7 mRNA 674 
levels in infected control or shBud13 BMDMs stimulated with VSV (MOI 5) across 24 hours.  (B) Same as 675 
in (A) except stimulated at an MOI of 10. Results are presented relative to those of Rpl32. (C) PFU/mL for 676 
viral supernatant from infected shBud13 (blue), control (red), shBud13 with Irf7 overexpression (yellow), or 677 
control with Irf7 overexpression (maroon) BMDMs.   Data is representative of two (A, B) or three 678 
independent experiments (C) and is shown as mean + SEM.  * denotes p < 0.05, ** denotes p < 0.01, and 679 
*** denotes p < 0.001 using a Student’s t test 680 
 681 
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 696 
Contact for Reagent and Resource Sharing 697 
 698 
Further information and requests for resources and reagents should be directed to and will be 699 
fulfilled by the Lead Contact, David Baltimore (baltimo@caltech.edu). 700 
 701 
Experimental Model and Subject Detail 702 
 703 
Animals 704 
The California Institute of Technology Institutional Animal Care and Use Committee approved all 705 
experiments. C57BL/6 WT mice were bred and housed in the Caltech Office of Laboratory Animal 706 
Resources (OLAR) facility.  C56BL6/J mice were sacrificed via CO2 euthanasia and sterilized with 707 
70% ethanol. Femur and tibia bones harvested and stripped of muscle tissue. Bone marrow cells 708 
were resuspended in 20mL of fresh DMEM. 2.5 *106 bone-marrow cells plated in a 150mm dish in 709 
20mL of BMDM Media (DMEM, 20% FBS, 30% L929 condition media, and 1% Pen/Strep) and 710 
grown at 5% CO2 and 37°C. BMDM media was completely replaced on day 3 as well as a 711 
supplemental addition of 5mL L929 condition media on day 5.   712 
 713 
Cell Culture 714 
 723 
Human embryonic kindey cells (HEK293T) from ATCC were cultured in DMEM supplemented with 724 
10% FBS and 1% Pen/Strep.  Cell line was maintened at 37°C in 5% CO2. 725 
 726 
Method Detail 727 
 728 
Knockdown Experiments  729 
BMDMs for knockdown experiments were grown as described above with a few additions. On days 3 730 
and 4, retrovirus encoding shRNAs were added to cells.  On day 5, cells were selected with 731 
puromycin (5ug/mL).  On day 8, following ~72 hours of puromycin treatment, media was removed 732 
and 10mL of PBS w/ 2mM EDTA was added.  Cells were lightly scraped and replated in either 6 well 733 
plates or 10-cm dishes depending on the experiment.  Cells were left in BMDM media overnight.  734 
The following day, cells were stimulated with either 20ng/mL of TNFα, 5ug/mL Poly(I:C) (Sigma), or 735 
ODN 1585 (1-5 µM) (InvivoGen). 736 
 737 
RNA Isolation: 738 
Total RNA was purified from BMDMs using TRIzol reagent (Ambion) as per the manufacturer’s 739 
instructions.  Genomic DNA in RNA purifications was eliminated through treatment with Turbo 740 
DNase (Thermo Fisher Scientific) for 30 min at 37°C.  0.1-1µg RNA and 1µM dT(30) oligo (d14-954: 741 
5’-AAGCAGTGGTATCAACGCAGAGTACT(30)) was heated at 80°C for 2.5min followed by snap 742 
cooling on ice. 10µL template-switch RT mix added (10µM template-switch oligo (TSO: 5’-743 
AAGCAGTGGTATCAACGCAGAGTACACArGrGrG), 20mM DTT, 2X ProtoScriipt II Reverse 744 
Transcriptase Reaction Buffer (NEB), 1mM dNTPs, 40U Murine RNAse Inhibitor (NEB), and 200U 745 
ProtoScript II (NEB) Reverse Transcriptase. Reaction incubated in thermocycler with the following 746 
program: 1. 42°C for 30min, 2. 45°C for 30min, 3. 50°C for 10min, followed by deactivation of RT for 747 
10min at 80°C.  748 
 749 
RNA Fractionation: 750 
Confluent 10-cm dish of mature BMDMs were scraped into 400µL cold NP-40 lysis buffer, APJ1 751 
(10mM Tris-HCl (pH 7.5), 0.08% NP-40, 150mM NaCl). Lysed cells layered onto 1mL cold sucrose 752 
322 cushion, APJ2 (10mM Tris-HCl (pH 7.5), 150mM NaCl, 24% w/v sucrose) and centrifuged for 753 
10min at 4°C and 13000 rpm. The supernatant from this spin represents the cytoplasmic RNA 754 
fraction, which is immediately added to 3 volumes of 100% ethanol and 2 volumes of buffer RLT (4M 755 
GuSCN, 325 0.1M β-mercaptoethanol, 0.5% N-lauroyl sarcosine, 25mM Na-citrate, pH7.2) and 756 
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stored at -80°C until ready to purify RNA. Pellet, containing intact nuclei, is resuspended in 500µL 757 
TRIzol reagent.  If the pellet was difficult to dissolve, it was heated at 50°C with occasional vortexing.  758 
100µL chloroform added and shaken vigorously for 15-20s; allowed to phase separate at room 759 
temperature for 5min. Tube centrifuged at 4°C and 12000 x g for 15min. Clear upper aqueous phase 760 
removed to a new tube, ensuring white DNA mid-phase is not removed, and is immediately added to 761 
3 volumes of 100% ethanol and 2 volumes of buffer RLT and stored at -80°C until ready to purify 762 
RNA. RNA is purified according to Qiagen RNeasy column protocol and eluted in 30µL nuclease-763 
free H2O. RNA samples are DNAse treated with Turbo-DNAse and stored at -80°C. 764 
 765 
Library preparation and RNA-Seq Analysis 766 
Limited PCR amplifications was performed prior to library preparation.  PCR reaction done with 767 
KAPA HiFi HotStart 2x ReadyMix, 5% cDNA, and 1µM primer (d14-955: 5’-768 
AAGCAGTGGTATCAACGCAGAGTACT).  Thermal cycler programmed for 120 seconds at 95°C as 769 
initial denaturation, followed by 14 cycles of 30sec at 95°C for denaturation, 30sec at 62.5°C as 770 
annealing, 150sec at 72°C for extension, and final extension at 72°C for 5 min.  PCR reactions 0.9X 771 
SeraMag and eluted in 25µL. Concentrations of purified library determined using Qubit High 772 
Sensitivity dsDNA kit (Invitrogen) as described.  Full length cDNA libraries were barcoded using the 773 
Nextera XT Tagmentation protocol (Illumina).  774 
 775 
RNA-Antisense Purification 776 
RNA antisense purification-mass spectrometry (RAP-MS) was performed as described in McHugh et 777 
al. with a few alterations.  Briefly, we designed three 90-mer DNA oligonucleotide probes that were 778 
antisense to the complementary target RNA sequence in both Irf7 and Actb transcripts.  Each probe 779 
was targeted to a different location on the transcript and modified with a biotin in order to enable 780 
capture of DNA:RNA hybrids on streptavidin coated magnetic beads.   781 
RNA Prep and Lysis: ~250million cells, or 25 150mm plates of BMDMs were used for each capture. 782 
Following stimulation with TNFα (20ng/ml) for 30 minutes, ~5-10 mL of PBS w/ 2mM EDTA was 783 
added to each plate and cells were removed by lightly scraping.  Cells were pelleted, resuspended in 784 
PBS, and poured into a new 150mm plate.  The cells were then crosslinked in Spectrolinker at 254 785 
nm wavelength with 0.8 J/cm2 (instrument setting: 8000 x 100 uJ/cm2).  Following crosslinking, cells 786 
were again pelleted, at which point the pellet could be frozen and stored at -80°C.  Cells were lysed 787 
in 2mL of lysis buffer per capture (10 mM Tris pH 7.5, 500 mM LiCl, 0.5% Triton X-100, 0.2% sodium 788 
dodecyl sulphate, 0.1% sodium deoxycholate) supplemented with Protease Inhibitor Cocktail (EMD 789 
Millipore) and 1000 U of Murine RNase Inhibitor (New England Biolabs).  We found the smaller the 790 
volume used per sample, the more efficient the capture was downstream and thus the minimum 791 
volume needed to lyse cells should be optimized.  Samples were incubated for 10 min on ice to 792 
allow lysis.  Following lysis, sample was passed through 20-gauge needle once and then 26-gauge 793 
needle 3-5 times to disrupt the pellet and shear genomic DNA.  In between passing the sample 794 
through the 26-gauge needle, the sample was sonicated on ice with a microtip set at 5W power for a 795 
total of 30 s in intermittent pulses (0.7 s on, 1.3 s off).  Samples were then mixed with twice the 796 
lysate volume of 1.5x LiCl/Urea Buffer (the final buffer contains 10 mM Tris pH 7.5, 500 mM LiCl, 797 
0.5% Triton X-100, 0.2% SDS, 0.1% deoxycholate, 4 M urea). Lysates were incubated on ice for 10 798 
min then cleared by centrifugation for 10 min at 4,000g. 799 
Pre-clearing lysate: BioMag streptavidin beads (Bang Laboratories Inc.) were first washed 3x in 800 
0.25-0.5ml of 500mM LiCl/4M Urea buffer (10 mM Tris pH 7.5, 500 mM LiCl, 0.5% Triton X-100, 801 
0.2% SDS, 0.1% deoxycholate, 4 M urea).  50ul of beads were added to each sample and the 802 
samples were incubated at 37°C for 30 min with shaking.  Streptavidin beads were then magnetically 803 
separated from lysate samples using a magnet.  The beads used for preclearing lysate were 804 
discarded and the lysate sample was transferred to fresh tubes twice to remove all traces of 805 
magnetic beads.  Input for quality control experiments can be removed at this point.   806 
Hybridization, Capture of Probes and Elution of Associated Protein: Following pre-clearing, the 807 
biotinylated 90-mer DNA oligonucleotide probes specific for the RNA target of interest (vary per 808 
sample but ~5ul of 25uM per probe) were heat-denatured at 85°C for 3 min and then snap-cooled on 809 
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ice.  Probes and pre-cleared lysate were mixed and incubated at 55°C with shaking for 2 h to 810 
hybridize probes to the capture target RNA.  500mL of washed streptavidin beads (Bang 811 
Laboratories Inc.) were then added to each sample at 55°C with shaking for 30 mins.  Beads with 812 
captured hybrids were washed 6 times with LiCl/Urea Hybridization Buffer.  If needed, 1% of the 813 
beads can be removed for qPCR quality control experiment.  TRIzol reagent can be added directly to 814 
beads to elute RNA.  Beads were then resuspended in Benzonase Elution Buffer (20 mM Tris pH 815 
8.0, 2 mM MgCl2, 0.05% NLS, 0.5 mM TCEP) and 125 U of Benzonase nonspecific RNA/DNA 816 
nuclease was added.  Incubation occurred for 1-2 h at 37°C.  Beads were then separated from the 817 
sample using a magnet.  Supernatant was collected.  Contaminant beads were removed by 5 rounds 818 
of magnetic separation on supernatant.  Protein was precipitated overnight at 4°C with 10% 819 
trichloroacetic acid (TCA). TCA treated protein elution samples were pelleted by centrifugation for 30 820 
min at 20,000g, then washed with 1 ml cold acetone and recentrifuged. Final protein elution pellets 821 
were air dried to remove acetone, resuspended in fresh 8 M urea dissolved in 40 ml of 100 mM Tris-822 
HCl pH 8.5, and stored at -20°C. 823 
Mass Spec Prep. and Analysis Performed as in McHugh et al. with few exceptions.  Instead of 824 
SILAC we label proteins at the mass spec prep step using TMT (Thermo).  After desalting on a 825 
Microm Bioresources C8 peptide MicroTrap column and lyophilization of peptide fraction, lyophilized 826 
protein pellets were resuspended in 100mM TEAB at a concentration of 1ug/ul.  We then added 827 
1.64ul of TMT labelling reagent to each ug of sample.  The reaction was incubated for one hour at 828 
room temperature.  The reaction was quenched with 0.32ul of 5% hydroxylamine per ug of protein 829 
used and incubated for 15 mins at room temperature.  Following quenching, the samples were 830 
mixed, desalted as before, lyophilized, and mass spec was performed on Orbitrap Fusion mass 831 
spectrometer using a TMT instrument method as described in Liu et al.34 832 
Raw files were searched using MaxQuant (v. 1.5.3.30) against the UniProt mouse database (59550 833 
sequences) and a contaminant database (248 sequences). TMT 6plex was selected as the 834 
quantitation method with a reporter mass tolerance of 0.3. Oxidation of methionine and protein N-835 
terminal acetylation were variable modifications and carbamidomethylation of cysteine was fixed 836 
modification. A 1% protein and peptide false discovery rate as estimated by the target-decoy 837 
approach was used for identification. 838 
 839 
RNA Immunoprecipitation 840 
RNA immunoprecipitations were performed as previously described.  Between 5-10 confluent 15 cm2 841 
dishes of BMDMs per sample were stimulated with either 20ng/mL of TNFα for 30 minutes or 842 
5ug/mL Poly(I:C) for 12 hours.  Following stimulation, proteins were cross-linked to DNA by adding 843 
formaldehyde directly to the media to a final concentration of 0.75%, with light shaking at room 844 
temperature for 10 mins.  To quench the crosslinking reaction, glycine to a final concentration of 125 845 
mM was added to the media and incubated with shaking for 5 mins at room temp.  Media was then 846 
aspirated and cells were rinsed twice with 10 mL of cold PBS.  Following the second wash, cells 847 
were scraped into 10mL of PBS and spun down gently ( 5 min, 4°C, 1,000xg).  Final cell pellet was 848 
resuspended in 0.1-1mL of polysome lysis buffer (100 mM KCl, 5 mM MgCl2, 10 mM HEPES (pH 849 
7.0), 0.5% NP40, 1 mM DTT, 100 U.ml RNase Inhibitor (NEB)) supplemented with Protease Inhibitor 850 
Cocktail (EMD Millipore).  At this point the mRNP lysate was frozen.  If needed, passing the lysate 851 
through a small gauge needle can help with lysate.  Protein-G beads were pre-treated at 4°C with 852 
NT2 (50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM MgCl2, 0.05% NP40) supplemented with 5% 853 
BSA to a final ratio of 1:5 for at least 1h before use.  Appropriate amount of antibody per sample 854 
(optimized based on antibodyused but typically ~1-10ug) was added ot 250-500ul of bead/BSA 855 
slurry and incubated at 4°C.  Following incubation, beads were spun down and washed with 1 ml of 856 
ice-cold NT2 buffer 4–5 times.  Following final wash, beads were resuspended in 850ul of NT2 and 857 
supplemented with 200U of RNase inhibitor, 10 μl of 100 mM DTT and EDTA to 20 mM.  Frozen 858 
lysate was thawed and centrifuged at 15,000*g for 15 mins.  The cleared supernatant was removed 859 
and 100ul was added to the prepared beads.  Input removed at this step.  Beads and lysate were 860 
incubated for 4h at 4°C with mixing.  The beads were washed 4-5 times with ice-cold NT2 and then 861 
resuspended in 100ul of NT2 buffer.  4ul of 5M NaCl was added incubated with shaking at 65°C for 2 862 
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hours. NT2 buffer can also be supplemented with 30 μg of proteinase K to release the RNP 863 
component. RNA was isolated by adding TRIzol reagent (Ambion) as per the manufacturer’s 864 
instructions.  RNA was reverse transcribed and quantification was performed using TaqMan qPCR.   865 
 866 
Immunoblot 867 
BMDM samples were prepared as described previously.  On day 8, they were plated at similar 868 
density.  Following adherence, BMDMs were stimulated with Poly(I:C) or CpG for the indicated time.  869 
Cells were scraped into subcellular fractionation buffer (20mM HEPES (pH 7.4), 10 mM KCl, 2 mM 870 
MgCl2, 1mM EDTA, 1 mM EGTA).  The cells were then passed through a 27 gauge needle 10 times, 871 
incubated on ice for 10 mins, and spun down at 720xg for 5 min.  The pellet contained the nuclei, 872 
which was washed with fractionation buffer, passed through a 25 gauge needle 10 times, and 873 
centrifuged again at 720xg for 10 mins.  The resulting pellet was resuspended in RIPA lysis buffer.  874 
Queal amounts of proteins were analyzed by immunoblot using the following reagents:  anti-IRF7 875 
(Millipore, ABF130), anti-Lamin B1 HRP conjugate (Cell Signalling, D9V6H), and anti-rabbit IgG 876 
HRP conjugate (Cell Signalling). 877 
 878 
Viral Plaque Assays 879 
Plaque assays were done one Vero cells.  2.5*105 vero cells were plated in a 12 well plate the night 880 
before infection.  Prior to infection, cells were checked to ensure confluence.  VSV was serially 881 
diluted and infected in 12 well plate for 1 h.  VSV was then removed and cells were layered carefully 882 
with DMEM supplemented with 2% FBS and 0.4% agarose.  Plate was incubated for 2 days, and 883 
then fixed with 10% formaldehyde, for 1 h to overnight.  Finally, agarose plugs were removed 884 
carefully and cells were stained with crystal violet.  885 
 886 
VSV-GFP Infection Experiment 887 
BMDMs were grown as described above in 150mm dishes.  On day 8, following ~72 hours of 888 
puromycin treatment, media was removed and 10mL of PBS w/ 2mM EDTA was added.  Cells were 889 
lightly scraped and 250,000 cells/well were replated in 12 well plates in BMDM media.  Cells were 890 
left for 12 hours to adhere.  Following adherence, VSV-GFP was added at the specified MOI for the 891 
specified amount of time.  Following the time-course, cells were lightly scraped, washed and spun 892 
down, and resuspended in PBS. Samples were analyzed on a MACSQuant10 Flow Cytometry 893 
machine (Miltenyi).  Gating strategy depicted in Fig. 7.  894 
 895 
VSV-GFP Viral Supernatant Experiment 896 
BMDMs were grown as described above in 150mm dishes.   On day 8, following ~72 hours of 897 
puromycin treatment, media was removed and 10mL of PBS w/ 2mM EDTA was added.  Cells were 898 
lightly scraped and 400,000 cells/well were replated in 12 well plates in BMDM media.  Cells were 899 
left to adhere for 12 hours, before being infected at an MOI of 25 for 8 hours.  Following infection, 900 
virus was removed and the cells were washed with PBS three times.  Then, 500ul of BMDM media 901 
(DMEM, 20% FBS, 30% L929 condition media, and 1% Pen/Strep) was added to each well.  18 902 
hours later, media was collected and stored at -80°C.  To titer viral supernatant, Vero cells were 903 
plated in a 96-well plate at 30,000 cells per well in 90ul of D10 media.  12 hours after plating, 90ul 904 
supernatant was added to the 90ul of D10 at different dilutions.  PFU/mL was calculated from a 905 
standard curve with a virus of known concentration. 906 
 907 
Quantification and Statistical Analysis 908 
All statistical analysis was performed in Python (version 2.7.9).  Unless otherwise indicated in figure 909 
legends, statistical significance measurements were marked as follows: * denotes p < 0.05, ** denotes 910 
p < 0.01, *** denotes p < 0.001, and n.s. denotes not significant.  RNA-Seq expression and splicing 911 
analysis as well as eCLIP analysis is described in more detail below. 912 
 913 
 914 
RNA-Sequencing Analysis 915 
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Sequencing was performed on a HiSeq 2500 High Throughput Sequencer (Illumina).  Single-end 50-916 
mer reads were aligned using Tophat v2.1.1.35 Gene expression was determined using Cufflinks 917 
v2.2.1 and the FPKM (Fragments Per Kilobase Million) metric.36 918 
 919 
Splicing Ratio and ΔSR Calculation 920 
A custom script was written in Python using the HTSeq37 library to calculate Splicing Ratio. First, 921 
reads that map to an intron or exon feature are summed.  To map to a feature, reads must have >1 922 
bp overlap with the feature.  If a read maps to more than one feature, such as in the case of a splice 923 
junction read, the read is split between the features.  SR is calculated by taking the length 924 
normalized number of reads that map to each intron, divided by the average length normalized 925 
number of exon reads plus the length normalized intron value.  When SR is equal to 0, this indicates 926 
a junction is completely spliced.  In contrast, large SR values indicate intron retention.   927 
We use the SR value to calculate ΔSR, which is equal to SR(shBud13) – SR(Ctl).  Values greater 928 
than 0 indicate the junction is more unspliced in the shBud13 sample, whereas values less than 0 929 
indicate the junction is more unspliced in the Ctl sample.  For the global analysis, in order for the 930 
ΔSR of a junction to be considered, it must pass through a number of filters.  To account for 931 
transcripts that are annotated in Ensembl version 67, but not expressed, we set an FPKM threshold 932 
of 15.  Further, a local normalized read count threshold on the upstream/downstream exons was 933 
implemented to ensure a level of sequencing depth needed to get accurate splicing values.  To pass 934 
this threshold, the sum of the reads that map to the the upstream/downstream exons divided by the 935 
length of these exons must be  0.25.  936 
 937 
ISG and Genome-Wide Analysis 938 
ISGs used in Fig. 4 E-H were selected based on induction 2 hours after in vivo IFNa injection.15  We 939 
classified ISGs to be any gene with a fold change  3.5 following 2 hours of induction.  Intron RPKM 940 
was calculated using a custom python script with the HTSeq library.  In Fig. 5a, transcripts from the 941 
30 min. TNFα data-set that had a junction with a ΔSR value above 0.15 were sorted into an 942 
‘increased IR’ category (ΔSR >0.15), whereas all other transcripts were sorted into an unaffected 943 
category (ΔSR <-0.15).  The selected data-set is representative of all time-points from the TNFα, 944 
Poly(I:C) and CpG datasets.  A maximum entropy model was used to calculate 3’ and 5’ splice site 945 
strengths.12 To determine differences in 5’ splice site sequence for Bud13 dependent junctions, the 946 
nine base pair sequence near the 5’ splice site junctions for junctions that had a ΔSR >0.15 was 947 
compared to all expressed junctions (FPKM>1).  The top Bud13 dependent junctions were plotted 948 
based on the average ΔSR value across all time-points from the TNFα data-set (Fig. 5D) as well as 949 
the Poly (I:C) data-set (Fig. SH).  Junctions that had a ΔSR value <0.15 in a time-point were filtered 950 
out in the TNFα data-set, while junctions that had a ΔSR value <0.15 in two time-points were filtered 951 
out in the Poly (I:C) data-set.  The zero time-point was removd for the transcripts induced by the 952 
stimulant (Irf7 and Cd14).  For the comparison of alternative splicing events, rMATs38 was used on 953 
the TNFα data-set.  Splicing events were deemed significant if p<0.05 and FDR<0.1 for all time-954 
points.  SVMBPfinder was used to determine BP related features (BP strength and distance from BP 955 
to 3' splice site).39  956 
 957 
eCLIP 958 
Data for eCLIP experiments were downloaded from ENCODE Project Consortium.18  Analysis of 959 
eCLIP data is the same as has been described previously.40  Fold change of eCLIP read density 960 
compared to input read density along a normalized intron was calculated using ngs.plot.41  Peaks 961 
were called using CLIPper.42  Peaks were deemed significant if they were >3-fold enriched and had 962 
p-value<10-5.  Peak locations were determined using a custom python script with the HTSeq library.  963 
Enriched GO terms were determined using Seten.43 964 
 965 
 966 
 967 
Data and Software Availability 968 
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 969 
The next-generation sequencing data reported in this study will be deposited to the Gene Expression 970 
Omnibus (GEO).  Upon completion of deposit, the accession number for this data will be provided. 971 
 972 
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Figure 4: Bud13	knockdown	alters	the	type	I	interferon	response
Control
shBud13
shBud13
720	min.
Nuclear
Control
720	min.
Nuclear
shBud13
720	min.
Cytoplasmic
Control
720	min.
Cytoplasmic
L.
Int
ro
n 1
Int
ro
n 2
Int
ro
n 3
Int
ro
n 4
Int
ro
n 5
Int
ro
n 6
Int
ro
n 7
Int
ro
n 8
-0.2
-0.1
0.0
0.1
0.2
0.3
ΔS
R
(B
ud
13
K
D
 - 
C
on
tro
l)
B.
0 15 60 24
0
72
0
14
40
-0.2
0.0
0.2
0.4
Time (mins.)
M
ed
ia
n
Lo
g 2
 E
xp
re
ss
io
n 
Fo
ld
 C
ha
ng
e
0 500 1000 1500
0
5
10
15
20
Time (mins.)
FP
K
M
 
Fo
ld
 C
ha
ng
e
Control
shBud13
C.
0
72
0
14
40
0.00
0.01
0.02
0.03
0.04
IF
N
α 
m
R
N
A 
(F
ol
d)
Control
shBud13
**
***
*
0
72
0
14
40
0.000
0.005
0.010
0.015
0.020
0.025
IF
N
β 
m
R
N
A 
(F
ol
d)
Control
shBud13
**
***
***
I.
K.
G. H. I.
D.
All rights reserved. No reuse allowed without permission. 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/443820doi: bioRxiv preprint first posted online Oct. 15, 2018; 
Im
p4
Ps
me
1
Ps
ma
3
Dp
p7 Fli
i
Irf7
Em
g1
Hn
rnp
c
Kif
5bNx
f1
Hm
ox
2
Ma
f1
Cr
eb
3
Cd
14
Rp
l10
Ee
f1d
0.0
0.2
0.4
0.6
0.8
1.0
ΔS
R 
(s
hB
ud
13
 - 
Ct
l)
5’SS
(Expressed Junctions)
5’SS
(Bud13 Affected Junctions)
3 4 5 6 7 8 9 10
0.0
0.5
1.0
1.5
2.0
2.5
Weak Junction Threshold
(MaxEnt Score)
Mean SR Diff. < Threshold 
Mean SR Diff. Total
3' Splice Site
5' Splice Site
D.
E. G.
Figure 5:	Global	analysis	of	the	role	of	Bud13.
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Figure 6: Bud13	interacts	with	Bud13	dependent	 junctions	near	the	3’	splice	site.	
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Figure 7: Bud13	knockdown	alters	the	BMDM	response	 to	VSV.	
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FIGURE LEGENDS 
Figure 1: Irf7 contains a weak intron that is following many forms of stimulation.  (A) Histogram of 
mapped reads corresponding to the TNFα-induced expression of Irf7.  The poorly spliced fourth intron is 
highlighted.  For all read density plots, reads are histogrammed in log10 scale and normalized to the 
maximum value across the stimulation.  (B) Comparison of Irf7 splice donor and acceptor sites in mice, 
rats, and humans.  (C-F) Histogram representing the intron length (C), intron GC content (D), flanking 
exon GC content (E), or 5’ splice site strength of introns of expressed in BMDMs.  Red represents 
location of Irf7 intron 4 (C, D, F) or upstream exon (E). Black line represents downstream exon (E). (G, H) 
Histogram of mapped reads corresponding to the IFNα (G) and poly(I:C) (H) induced expression of Irf7 
focused on the slow splicing fourth intron. (I) Outline of Splicing Ratio (SR) metric. (J) Splicing ratio for all 
introns in Irf7 plotted against time stimulated with TNFα.   
 
Figure 2: RAP-MS and RIP identifies Bud13 as an RNA binding protein that interacts with IRF7 
mRNA.  (A) Outline of the RAP-MS procedure used to identify RNA-binding proteins on transcritps of 
interest. (B)  TMT ratio (Irf7/Actb) for proteins identified as enriched on either Irf7 (TMT ratio >1) or Actb 
(TMT ratio <1) transcripts.  (C) RT-qPCR analysis of transcripts captured via RAP for Irf7 (blue) and Actb 
(gold) probes.  (D) RIP followed by RT-qPCR for Irf7 and Rpl32 in TNFα stimulated BMDMs.  Shown is 
the relative enrichment of transcripts captured in Bud13 RIP as compared to Rabbit IgG RIP. (E) Same as 
(d) except stimulation with poly(I:C).  Data are representative of two independent experiments ((C-E), 
mean + SEM). *P < 0.05, **P < 0.01 and ***P < 0.001 (t-test).  
 
Figure 3: Bud13 knockdown leads to increased retention in the poorly splicing intron of Irf7.  (A) 
Histogram of mapped reads corresponding to the TNFα-induced expression of Irf7.  The poorly spliced 
fourth intron is highlighted.  shBud13 samples are shown in green.  Control samples are shown in grey. 
(B) ΔSRs calculated for each junction in the Irf7 transcript.  The ΔSR of intron 4 as compared to all other 
junctions is significant (Student’s t-test, p<0.001).  No other pairwise comparison is significant.  (C) 
Splicing gel from RNA extracted from BMDMS stimulated for 30 mins. TNFα (top).  Quantification of 
splicing gel (bottom).  (D) Irf7 FPKM fold change with respect to time stimulated.  shBud13 is shown in 
green, control is shown in grey. Data is representative of two independent experiments (C) and is 
represented as mean + SEM.  * denotes p < 0.05, ** denotes p < 0.01, and *** denotes p < 0.001 using a 
Student’s t test. 
Figure 4: Bud13 knockdown alters the type I interferon response. (A) Histogram of mapped reads 
corresponding to the TNFα-induced expression of Irf7.  The poorly spliced fourth intron is highlighted.  
shBud13 samples are shown in blue. Control samples are shown in grey. (B) ΔSRs calculated for each 
junction in the Irf7 transcript.  The ΔSR of intron 4 as compared to all other junctions is significant 
(Student’s t-test, p<0.001).  No other pairwise comparison is significant.  (C) Irf7 FPKM fold change with 
respect to time stimulated.  shBud13 is shown in blue, control is shown in grey.  (D) Immunoblot analysis 
of Irf7 protein following 720 mins. poly(I:C) stimulation (left).  Quantification relative to ActB (right). (E) 
Log2 expression fold change (shBud13/control) for 119 ISGs in unstimulated BMDMs (median = 0.1655). 
(F) As in (E) for stimulated BMDMs (720 mins poly(I:C) (median = -0.1007). Wilcoxon rank-sum between 
(E) and (F), P< .001.  (G) Median log2 expression fold change (shBud13/control) for ISGs in unstimulated 
BMDMs, and BMDMs stimulated with Poly(I:C) 15, 60, 240, 720, and 1440 mins.  Bars represent 95% CI.  
(Wilcoxon rank-sum, P< .001, for any of the ‘early’ time-points (0, 15, 60 mins) compared to any of the 
‘late’ time-points (240, 720, 1440 mins). (H) RT-qPCR analysis of IFNα mRNA levels in unstimulated 
BMDMs and BMDMs stimulated with poly(I:C) for 720 mins and 1440 mins. (I) Same as (H) for IFNβ. (J) 
Nuclear fraction (top) and cytoplasmic fraction (bottom) histograms of mapped reads corresponding to the 
poly(I:C)-induced expression of Irf7 (720 mins). The poorly spliced fourth intron is highlighted.  shBud13 
samples are shown in blue.  Control samples are shown in grey. Nuclear ΔSR = 0.35. (K) Nuclear and 
cytoplasmic RPKM for Irf7 intron 4 from fractionated BMDMs stimulated with poly(I:C).  (L) Cytoplasmic 
Irf7 FPKM for control (grey) and shBud13 BMDMs stimulated with poly(I:C).  Data is representative of four 
independent experiments (H, I) and is represented as mean + SEM.  * denotes p < 0.05, ** denotes p < 
0.01, and *** denotes p < 0.001 using a Student’s t test.  Results are presented relative to those of Rpl32 
(H,I). 
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Figure 5: Global analysis of the role of Bud13. (A) Ranked bar chart showing genes with a junction most 
affected by Bud13 knock-down in all samples during TNFα stimulation.  See S7 for histograms relating to 
most affected junctions. (B) Grouped bar chart depicting the number of genes that have a single Bud13 
affected junction vs. multiple Bud13 affected junctions using three different ΔSR thresholds.  (C) 
Transcripts were classified as ‘Bud13 dependent’ if they had a junction with a ΔSR. >0.15.  The log2 
expression fold change (FPKM shBud13/ FPKM control) for each gene represented by the transcripts in 
the ‘Bud13 dependent’ category as well as all other genes is shown.  Median ‘increased IR’ = -0.5084.  
Median ‘decreased IR’ = -0.2170.  (Wilcoxon rank-sum, P< .01).  (D)  Mean ΔSR. for junctions below the 
indicated threshold (x-axis) vs. mean ΔSR. for all junctions.  Threshold applied for the 5’ splice site (blue) 
and the 3’ splice site (green). (E) 5’SS motif for all expressed junctions as compared to junctions that show 
retention upon Bud13 knockdown (ΔSR. > 0.15). (F) Size of intron for introns retained upon Bud13 
knockdown (ΔSR. > 0.15) (blue), in introns located in the same transcript as those affected by Bud13 
(green), and in introns from all expressed transcripts (orange). (G) Same as (F) for GC content.  (H) 
Flanking exon GC content for exons that flank introns retained upon Bud13 knockdown (ΔSR. > 0.15) 
(dark green) as compared to exons that flank introns from all expressed transcripts (light green).  (I) 
Distance from the branch point to the 3’ splice site for introns retained upon Bud13 knockdown (ΔSR. > 
0.15) (dark blue) as compared to introns from all expressed transcripts (light blue).  (F-I) data from BMDM 
TNFα stimulation. Box plots show median (center line), interquartile range (box) and tenth and ninetieth 
percentiles.  *P < 0.05, **P < 0.01 and ***P < 0.001 (Mann-Whitney U-test).  
Figure 6: Bud13 interacts primarily near the 3’ splice site of small, GC rich introns. (A) eCLIP-seq 
read density plots in K562 cells.  Bud13 density plot over all expressed junctions shown in blue (top), 
Bud13 density plot over Bud13 dependent junctions shown in red (top). Sf3b4 density plot over all 
expressed junctions shown in maroon (middle), and Prpf8 density plot over all expressed junctions is 
shown in green (bottom).  (B) Same as in (A) but for Hep G2 cells.  (C) Bud13 eCLIP-seq peak 
distribution.  Peaks fell within either intronic regions, intron-exon junctions, or exonic regions.  Peaks that 
fell within intron-exon junction were further classified as 5’ junction peaks or 3’ junction peaks (bottom).  
(D) Same as (C) but for Hep G2.  (E)  Size of all introns in expressed transcripts for the given cell line 
(dark blue) vs size of introns with overlapping eCLIP peak (maroon).  Shown in K562 (left) and Hep G2 
(right) cells.  Box plots show median (center line), interquartile range (box) and tenth and ninetieth 
percentiles (whiskers).  *P < 0.05, **P < 0.01 and ***P < 0.001 (Mann-Whitney U-test). (F) Same as (E) 
for GC content.  (G) GO terms (biological process) enriched among Bud13 eCLIP peaks in K562(dark 
blue) and Hep G2 (maroon) cells. 
Figure 7: Bud13 knockdown alters the BMDM response to VSV. (A) RT-qPCR analysis of Irf7 mRNA 
levels in infected control or shBud13 BMDMs stimulated with VSV (MOI 5) across 24 hours.  (B) Same as 
in (A) except stimulated at an MOI of 10. Results are presented relative to those of Rpl32. (C) PFU/mL for 
viral supernatant from infected shBud13 (blue), control (red), shBud13 with Irf7 overexpression (yellow), or 
control with Irf7 overexpression (maroon) BMDMs.   Data is representative of two (A, B) or three 
independent experiments (C) and is shown as mean + SEM.  * denotes p < 0.05, ** denotes p < 0.01, and 
*** denotes p < 0.001 using a Student’s t test 
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Figure S1: Splicing	Ratios	across	all	junctions	 in	Irf7
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Figure S2: shBud13	knocks	down	Bud13	protein	and	mRNA.
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Figure S3: Irf7	Intron	4	is	the	most	Bud13	knockdown	affected	junction	of	all	ISGs.
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Figure S4: Bud13	knockdown	alters	the	type	I	interferon	response	in	response	to	CpG
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Figure S5: BMDM	fractionation	and	effect	of	Bud13	on	nuclear	Irf7	splicing
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Figure	S6:	Histograms	of	mapped	reads	corresponding	to	hits	identified	in	TNFα	and	PIC	data-sets.
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Figure S7: Supplemental	 global	analysis	of	 shBud13
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Figure S8: Bud13 dependent IR events in Hep G2 and K562 cells.
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Figure S9: Bud13	knockdown	alters	the	BMDM	infection	via	VSV.	
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Figure S10: Knockdown	of	other	RES	complex	proteins.	
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